Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis

by Nakamura, T., Ito, M., Hashimoto, J., Shinomiya, K., Asao, Y., Katsumata, K., Hagino, H., Inoue, T., Nakano, T., Mizunuma, H.
Published 2015

Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1–S cell cycle transition in radioresistance of perinecrotic tumor cells

by Zhu, Y, Zhao, T, Itasaka, S, Zeng, L, Yeom, C J, Hirota, K, Suzuki, K, Morinibu, A, Shinomiya, K, Ou, G, Yoshimura, M, Hiraoka, M, Harada, H
Published 2013